The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
Open accessAbstract
Anti-programmed cell death 1 (PD-1) or anti-PD-ligand (L) 1 drugs, as classic immune checkpoint inhibitors, are considered promising treatment strategies for tumors. In clinical practice, some cancer patients experience drug resistance and disease progression in the process of anti-PD-1/PD-L1 immunotherapy. Tumor-associated macrophages (TAMs) play key roles in regulating PD-1/PD-L1 immunosuppression by inhibiting the recruitment and function of T cells through cytokines, superficial immune checkpoint ligands, and exosomes. There are several therapies available to recover the anticancer efficacy of PD-1/PD-L1 inhibitors by targeting TAMs, including the inhibition of TAM differentiation and re-education of TAM activation. In this review, we will summarize the roles and mechanisms of TAMs in PD-1/PD-L1 blocker resistance. Furthermore, we will discuss the therapies that were designed to deplete TAMs, re-educate TAMs, and intervene with chemokines secreted by TAMs and exosomes from M1 macrophages, providing more potential options to improve the efficacy of PD-1/PD-L1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mu, J., Sun, P., Ma, Z., & Sun, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2170-4 · Cited by 36
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“As one of the most important immunosuppressive cytokines secreted by M2 TAMs, TGF-b changes the TME by limiting the infiltration of T cells to inhibit antitumor immunity (8).”
BackgroundMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Teicher, B. A., & Fricker, S. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2329 · Cited by 1,449
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748
Exosome mediated communication within the tumor microenvironment
Milane, L., Singh, A., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.029 · Cited by 742
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 683
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Bhatnagar, S., Shinagawa, K., Castellino, F. J., & Schorey, J. S. (2007) · Blood · doi:10.1182/blood-2007-03-079152 · Cited by 633
Imaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Multifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 591
Bockorny, B., Semenisty, V., Macarulla, T., Borazanci, E., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 557
Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., & Di, W. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 528
Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Choo, Y. W., Kang, M., Kim, H. Y., Han, J., Kang, S., Lee, J.-R., Jeong, G.-J., Kwon, S. P., Song, S. Y., Go, S., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b02446 · Cited by 465
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Lin, C., He, H., Liu, H., Li, R., Chen, Y., Qi, Y., Jiang, Q., Chen, L., Zhang, P., Zhang, H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316324 · Cited by 418
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Zheng, P., Luo, Q., Wang, W., Li, J., Wang, T., Wang, P., Chen, L., Zhang, P., Chen, H., Liu, Y., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0465-5 · Cited by 381
Designing Hydrogels for On-Demand Therapy
Oliva, N., Conde, J., Wang, K., & Artzi, N. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00536 · Cited by 371
Ying, X., Wu, Q., Wu, X., Zhu, Q., Wang, X., Jiang, L., Chen, X., & Wang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9246 · Cited by 348
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles
Wei, Z., Zhang, X., Yong, T., Bie, N., Zhan, G., Li, X., Liang, Q., Li, J., Yu, J., Huang, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20723-x · Cited by 342
Binenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G., Shlomi, T., & Gil, Z. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0124 · Cited by 337
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., Wojno, K., Snyder, L. A., Yan, L., & Pienta, K. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1286 · Cited by 333
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Ren, D., Hua, Y., Yu, B., Ye, X., He, Z., Li, C., Wang, J., Mo, Y., Wei, X., Chen, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1144-6 · Cited by 316
Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment
Whiteside, T. L. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.003 · Cited by 308
Dai, X., Lu, L., Deng, S., Meng, J., Wan, C., Huang, J., Sun, Y., Hu, Y., Wu, B., Wu, G., et al. (2020) · Theranostics · doi:10.7150/thno.47137 · Cited by 288
Wu, Q., Zhou, L., Lv, D., Zhu, X., & Tang, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0739-0 · Cited by 281
Dong, L., Chen, C., Zhang, Y., Guo, P., Wang, Z., Li, J., Liu, Y., Liu, J., Chang, R., Li, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.016 · Cited by 278
Chen, X., Ying, X., Wang, X., Wu, X., Zhu, Q., & Wang, X. (2017) · Oncology Reports · doi:10.3892/or.2017.5697 · Cited by 269
Wan, C., Sun, Y., Tian, Y., Lu, L., Dai, X., Meng, J., Huang, J., He, Q., Wu, B., Zhang, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9789 · Cited by 251
Haney, M. J., Zhao, Y., Jin, Y. S., Li, S. M., Bago, J. R., Klyachko, N. L., Kabanov, A. V., & Batrakova, E. V. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09884-9 · Cited by 245
Santoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 237
Berberine-loaded M2 macrophage-derived exosomes for spinal cord injury therapy
Gao, Z.-S., Zhang, C.-J., Xia, N., Tian, H., Li, D.-Y., Lin, J.-Q., Mei, X.-F., & Wu, C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.018 · Cited by 224
Konkel, J. E., Zhang, D., Zanvit, P., Chia, C., Zangarle-Murray, T., Jin, W., Wang, S., & Chen, W. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.015 · Cited by 220
Gomez-Roca, C. A., Italiano, A., Le Tourneau, C., Cassier, P. A., Toulmonde, M., D’Angelo, S. P., Campone, M., Weber, K. L., Loirat, D., Cannarile, M. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz163 · Cited by 213
Biological drug and drug delivery-mediated immunotherapy
Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.018 · Cited by 211
Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel
Jin, H., Wan, C., Zou, Z., Zhao, G., Zhang, L., Geng, Y., Chen, T., Huang, A., Jiang, F., Feng, J.-P., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08148 · Cited by 201
Immunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
Sarode, P., Zheng, X., Giotopoulou, G. A., Weigert, A., Kuenne, C., Günther, S., Friedrich, A., Gattenlöhner, S., Stiewe, T., Brüne, B., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6105 · Cited by 191
Argyle, D., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 190
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Yin, C., Han, Q., Xu, D., Zheng, B., Zhao, X., & Zhang, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601479 · Cited by 178
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
Tu, M. M., Abdel-Hafiz, H. A., Jones, R. T., Jean, A., Hoff, K. J., Duex, J. E., Chauca-Diaz, A., Costello, J. C., Dancik, G. M., Tamburini, B. A. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01441-y · Cited by 178
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 175
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Beider, K., Bitner, H., Leiba, M., Gutwein, O., Koren-Michowitz, M., Ostrovsky, O., Abraham, M., Wald, H., Galun, E., Peled, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2207 · Cited by 171
Beaver, J. A., Hazarika, M., Mulkey, F., Mushti, S., Chen, H., He, K., Sridhara, R., Goldberg, K. B., Chuk, M. K., Chi, D.-C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30846-x · Cited by 171
Zhu, Z., Zhang, H., Chen, B., Liu, X., Zhang, S., Zong, Z., & Gao, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588552 · Cited by 167
Melanoma drug wins US approval
Ledford, H. (2011) · Nature · doi:10.1038/471561a · Cited by 163
Cui, X., Ma, C., Vasudevaraja, V., Serrano, J., Tong, J., Peng, Y., Delorenzo, M., Shen, G., Frenster, J., Morales, R.-T. T., et al. (2020) · eLife · doi:10.7554/elife.52253 · Cited by 163
M2 tumor‑associated macrophages promote tumor progression in non‑small‑cell lung cancer
Sumitomo, R., Hirai, T., Fujita, M., Murakami, H., Otake, Y., & Huang, C. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8068 · Cited by 160
Steitz, A. M., Steffes, A., Finkernagel, F., Unger, A., Sommerfeld, L., Jansen, J. M., Wagner, U. A. G., Graumann, J., Müller, R., & Reinartz, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2438-8 · Cited by 155
Mao, Y., Eißler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1912 · Cited by 151
Dammeijer, F. F., Lievense, L. A., Kaijen-Lambers, M. E. H., van Nimwegen, M., Bezemer, K., Hegmans, J. P., van Hall, T., Hendriks, R. W., & Aerts, J. G. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0309 · Cited by 150
New checkpoints in cancer immunotherapy
Ni, L., & Dong, C. (2017) · Immunological Reviews · doi:10.1111/imr.12524 · Cited by 149
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer
Cao, L., Che, X., Qiu, X.-S., Li, Z., Yang, B., Wang, S., Hou, K., Fan, Y., Qu, X., & Liu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199832 · Cited by 149
Wang, Z., Kang, W.-T., Li, O., Qi, F., Wang, J., You, Y., He, P., Suo, Z., Zheng, Y., & Liu, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.005 · Cited by 145
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
Xi, J., Huang, Q., Wang, L., Ma, X., Deng, Q., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0178-3 · Cited by 143
Li, Z., Suo, B., Long, G., Gao, Y., Song, J. T., Zhang, M., Feng, B., Shang, C., & Wang, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.572689 · Cited by 142
USP7: Novel Drug Target in Cancer Therapy
Wang, Z., Kang, W.-T., You, Y., Pang, J., Ren, H., Suo, Z., Liu, H., & Zheng, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00427 · Cited by 140
F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner
Yumimoto, K., Akiyoshi, S., Ueo, H., Sagara, Y., Onoyama, I., Ueo, H., Ohno, S., Mori, M., Mimori, K., & Nakayama, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78782 · Cited by 137
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., & Berardi, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.002 · Cited by 137
Wang, H., Alarcón, C. N., Liu, B., Watson, F., Searles, S. C., Lee, C. K., Keys, J., Pi, W., Allen, D., Lammerding, J., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00815-9 · Cited by 137
Kuklinski, L. F., Yan, S., Li, Z., Fisher, J. L., Cheng, C., Noelle, R. J., Angeles, C. V., Turk, M. J., & Ernstoff, M. S. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2169-1 · Cited by 127
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
Hensler, M., Kašíková, L., Fišer, K., Raková, J., Škapa, P., Laco, J., Láníčková, T., Pecen, L., Truxová, I., Vosahlikova, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000979 · Cited by 116
Komura, N., Mabuchi, S., Shimura, K., Yokoi, E., Kozasa, K., Kuroda, H., Takahashi, R., Sasano, T., Kawano, M., Matsumoto, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02628-2 · Cited by 114
Shi, G., Yang, Q., Zhang, Y., Jiang, Q., Lin, Y., Yang, S., Wang, H., Cheng, L., Zhang, X., Li, Y., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.010 · Cited by 113
Marchesi, F., Cirillo, M., Bianchi, A., Gately, M., Olimpieri, O. M., Cerchiara, E., Renzi, D., Micera, A., Balzamino, B. O., Bonini, S., et al. (2014) · Hematological Oncology · doi:10.1002/hon.2142 · Cited by 111
Ma, Y., Wu, T., Ling, C., Yu, F., Zhang, J., Cao, P., Gu, L., Wang, H., Xu, H. W., Li, L., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.02.005 · Cited by 111
Sumitomo, R., Hirai, T., Fujita, M., Murakami, H., Otake, Y., & Huang, C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.023 · Cited by 104
Dimeloe, S., Gubser, P. M., Loeliger, J., Frick, C., Develioglu, L., Fischer, M., Marquardsen, F. A., Bantug, G. R., Thommen, D. S., Lecoultre, Y., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav3334 · Cited by 99
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment
Srivastava, A., Rathore, S., Munshi, A., & Ramesh, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.020 · Cited by 95
Borggrewe, M., Grit, C., Den Dunnen, W. F. A., Burm, S. M., Bajramovic, J. J., Noelle, R. J., Eggen, B. J. L., & Laman, J. D. (2018) · Glia · doi:10.1002/glia.23517 · Cited by 91
The COX-2–PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas
Wei, J., Zhang, J., Wang, D., Cen, B., Lang, J. D., & DuBois, R. N. (2022) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0572 · Cited by 91
Li, L., Li, Y., Wang, L., Wang, F., Zhang, Z., Li, J., Yue, D., Chen, X., Yü, P., Huang, L. J., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30289 · Cited by 89
Li, J., Zhao, M. F., Sun, M. Z., Wu, S., Zhang, H., Dai, Y., & Wang, D. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14909 · Cited by 89
Li, L., Zhen, M., Wang, H., Sun, Z., Jia, W., Zhao, Z., Zhou, C., Liu, S., Wang, C., & Bai, C. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01287 · Cited by 87
Dai, X., Meng, J., Deng, S., Zhang, L., Wan, C., Lu, L., Huang, J., Hu, Y., Zhang, Z., Li, Y., et al. (2020) · Theranostics · doi:10.7150/thno.42385 · Cited by 86
Gómez, V., Eykyn, T. R., Mustapha, R., Flores‐Borja, F., Male, V. H., Barber, P. R., Patsialou, A., Green, R. J., Panagaki, F., Li, C. W., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aax4585 · Cited by 82
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
Mulligan, J. K., Rosenzweig, S. A., & Young, M. R. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b91c9c · Cited by 79
Cavalcante, R. S., Ishikawa, U., Silva, E. S., da Silva-Júnior, A. A., de Araújo, A. A., Cruz, L. J., Chan, A. B., & Júnior, R. F. D. A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15373 · Cited by 78
Bi, S., Huang, W., Chen, S., Huang, C., Li, C., Guo, Z., Yang, J., Zhu, J., Song, L., & Yu, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.050 · Cited by 76
Yang, F., Wang, T., Du, P., Fan, H., Dong, X., & Guo, H. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1163-9 · Cited by 72
mPGES-1 and ALOX5/-15 in tumor-associated macrophages
Weigert, A., Strack, E., Snodgrass, R. G., & Brüne, B. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9731-3 · Cited by 70
CCL 2 as a potential therapeutic target for clear cell renal cell carcinoma
Arakaki, R., Yamasaki, T., Kanno, T., Shibasaki, N., Sakamoto, H., Utsunomiya, N., Sumiyoshi, T., Shibuya, S., Tsuruyama, T., Nakamura, E., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.886 · Cited by 65
Liu, C., Zhang, W., Wang, J., Si, T., & Xing, W. (2021) · Cancer Science · doi:10.1111/cas.15101 · Cited by 61
Xie, X., Zhang, J., Zhongyuan, S., Liu, W., Hu, X., Qie, C., Chen, W., Wang, Y., Wang, L. L., Jiang, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563044 · Cited by 59
Joshi, S., Singh, A. R., Liu, K. X., Pham, T. V., Zulcic, M., Skola, D., Chun, H. B., Glass, C. K., Morales, G. A., Garlich, J. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1206 · Cited by 53
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells
Fortunato, O., Belisario, D. C., Compagno, M., Giovinazzo, F., Bracci, C., Pastorino, U., Horenstein, A. L., Malavasi, F., Ferracini, R., Scala, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02168 · Cited by 53
Kim, Y. J., Won, C. H., Lee, M. W., Choi, J. H., Chang, S. E., & Lee, W. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082500 · Cited by 51
Dai, X., Ruan, J., Guo, Y., Sun, Z., Liu, J., Bao, X., Zhang, H., Li, Q., Ye, C., Wang, X., et al. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.130109 · Cited by 49
Sherr, C. J., Ashmun, R., Downing, J. R., Ohtsuka, M., Quan, S., Golde, D. W., & Roussel, M. F. (1989) · Blood · doi:10.1182/blood.v73.7.1786.1786 · Cited by 48
Moreno-Vicente, J., Willoughby, J. E., Taylor, M. C., Booth, S. G., English, V., Williams, E. L., Penfold, C. A., Mockridge, C. I., Inzhelevskaya, T., Kim, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003735 · Cited by 47
BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages
Li, X., Fu, Y., Yang, B., Guo, E., Wu, Y., Huang, J. M., Zhang, X., Xiao, R., Li, K., Wang, B., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00089 · Cited by 44
Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma
Chen, L., Cao, M., Xiao, J., Ma, Q., Zhang, H., Cai, R., Miao, J., Wang, W.-Y., Zhang, H., Luo, M., et al. (2020) · Human Pathology · doi:10.1016/j.humpath.2019.12.007 · Cited by 36
Prostaglandins Regulate Melanoma-Induced Cytokine Production in Macrophages
Eisengart, C. A., MESTRE, J. R., Naama, H. A., Mackrell, P. J., Rivadeneira, D. E., Murphy, E. M., Stapleton, P. P., & DALY, J. M. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1686 · Cited by 35
The CCR2/MCP-1 Chemokine Pathway and Lung Adenocarcinoma
Mittal, P., Wang, L., Akimova, T., Leach, C. A., Clemente, J. C., Sender, M., Chen, Y., Turunen, B. J., & Hancock, W. W. (2020) · Cancers · doi:10.3390/cancers12123723 · Cited by 31
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Lim, Y. W., Coles, G. L., Sandhu, S. K., Johnson, D. S., Adler, A. S., & Stone, E. L. (2021) · BMC Biology · doi:10.1186/s12915-021-01034-z · Cited by 28
Sha, W., Olesch, C., Hanaka, H., Rådmark, O., Weigert, A., & Brüne, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.28181 · Cited by 24
Shih, C.-T., Shiau, C., Chen, Y., Chen, L.-J., Chao, T.-I., Wang, C., Huang, C., Hung, M., & Chen, K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.043 · Cited by 24
Wei, Y., Wang, X., Shengjun, Y., Shaohui, Z., & Hongzhen, Z. (2018) · PubMed · Cited by 20
Schoop, H., Bregenzer, A., Halske, C., Behrens, H., Krüger, S., Egberts, J., & Röcken, C. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.11.004 · Cited by 20
Absence of CCR2 reduces spontaneous intestinal tumorigenesis in the ApcMin /+ mouse model
Jala, V. R., Bodduluri, S. R., Ghosh, S., Chheda, Z. S., Singh, R., Smith, M. E., Chilton, P. M., Fleming, C., Mathis, S., Sharma, R., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33477 · Cited by 11
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
The role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
Shi, Y.-Y., Fan, G., Tan, R., Li, S., Sun, H.-B., Li, R., Yang, M., Gao, S., Liu, M., & Dai, M.-Y. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07073-y · Cited by 28
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
Metadata
- Authors
- Pu, Y., & Ji, Q.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-05-03
- Volume
- 13
- Pages
- 874589-874589
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4225373047
- Cited by
- 297
- References
- 133
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.